Alnylam Pharmaceuticals, Inc.
ALNY
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products includeā¦ read more
Healthcare
Biotechnology
21 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$291.48
Price-0.19%
-$0.55
1Y
Price
Market Cap
$38.916b
Large
Price/Earnings 3y Avg5y Avg
73.1x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+13.1%
EBITDA Margin+17.7%
Net Profit Margin+4.2%
Free Cash Flow Margin+13.1%
EBITDA Margin+17.7%
Net Profit Margin+4.2%
Free Cash Flow MarginRevenue
$4.287b
+15.4%
1y CAGR+34.5%
3y CAGR+45.0%
5y CAGREarnings
$577.217m
+84.0%
1y CAGR+111.2%
3y CAGR+98.7%
5y CAGREPS
$4.21
+80.7%
1y CAGR+108.6%
3y CAGR+97.0%
5y CAGRBook Value
$1.075b
$5.130b
Assets$4.054b
Liabilities$1.273b
DebtDebt to Assets
24.8%
2.1x
Debt to EBITDAFree Cash Flow
$641.338m
+37.8%
1y CAGR+343.0%
3y CAGR+284.0%
5y CAGRNo items found.
Press Releases
Statements and updates from the company